Investors are poised to add Hims & Hers Health Inc. (HIMS) Stock to their long term portfolios

Hims & Hers Health Inc. [HIMS] stock is trading at $6.71, up 1.51%. An important factor to consider is whether the stock is rising or falling in short-term value. The HIMS shares have gain 10.73% over the last week, with a monthly amount glided 59.76%, and seem to be holding up well over a long-time horizon.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

On 5, December 2022, Hims & Hers appoints first-ever Chief Pharmacy & Innovation Officer. In a post published today on Yahoo Finance, Dr. Scott Knoer was previously Chief Pharmacy Officer at Cleveland Clinic & CEO of the American Pharmacists Association.

From an analyst’s perspective:

Hims & Hers Health Inc. [NYSE: HIMS] stock has seen the most recent analyst activity on November 08, 2022, when SVB Leerink upgraded its rating to a Outperform but kept the price target unchanged to $5 for it. Previously, BofA Securities upgraded its rating to Buy on November 08, 2022, and elevated its price target to $8.50. On October 17, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $6 on the stock. Truist started tracking the stock assigning a Hold rating and suggested a price target of $7 on September 07, 2022. SVB Leerink initiated its recommendation with a Underperform and recommended $4 as its price target on July 15, 2022. Guggenheim started tracking with a Buy rating for this stock on April 14, 2022, and assigned it a price target of $10.

Hims & Hers Health Inc. [HIMS] stock has fluctuated between $2.72 and $7.28 over the past year. Currently, Wall Street analysts expect the stock to reach $7.72 within the next 12 months. Hims & Hers Health Inc. [NYSE: HIMS] shares were valued at $6.71 at the most recent close of the market. An investor can expect a potential return of 15.05% based on the average HIMS price forecast.

Analyzing the HIMS fundamentals

Hims & Hers Health Inc. [NYSE:HIMS] reported sales of 144.84 billion for the most recent quarter, which represents a growth of 87.10%. Gross Margin for this corporation currently stands at +73.72% with Operating Margin at -42.31%, Pretax Margin comes in at -40.75%, and Net Margin reading is -39.60%.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.55 points at the first support level, and at 6.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.90, and for the 2nd resistance point, it is at 7.09.

Hims & Hers Health Inc. [HIMS] reported earnings per share of -$0.1 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.1/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$0.08 per share as compared to estimates of -$0.07 per share, a difference of -$0.01 representing a surprise of -14.30%.

Ratios To Look Out For

For context, Hims & Hers Health Inc.’s Current Ratio is 4.10. On the other hand, the Quick Ratio is 3.24, and the Cash Ratio is 3.12. Considering the valuation of this stock, the price to sales ratio is 4.50, the price to book ratio is 4.01.

Transactions by insiders

The next item on our agenda is insider trading, which has seen 8 insider purchases totaling 171,337 shares and 11 insider sales totaling 140,315 shares over the past 3 months. Recent insider trading involved Boughton Soleil, Chief Legal Officer, that happened on Nov 14 when 2000.0 shares were sold. Chief Legal Officer, Boughton Soleil completed a deal on Nov 09 to sell 20000.0 shares. Meanwhile, Chief Legal Officer Boughton Soleil sold 5545.0 shares on Oct 18.